Latest News

Neladalkib shows promising efficacy in advanced ALK+ NSCLC, offering durable responses and manageable safety, potentially transforming treatment options.

The FDA has granted a full approval to tarlatamab-dlle for extensive-stage small cell lung cancer.

The FDA has approved sevabertinib for HER2-mutant nonsquamous non–small cell lung cancer.

The FDA has approved daratumumab and hyaluronidase plus chemotherapy for treating patients with newly diagnosed light chain amyloidosis.

Olutasidenib shows promising long-term efficacy and safety in treating relapsed or refractory mutant IDH1 acute myeloid leukemia, enhancing patient outcomes.

A novel sandwich therapy combining CD22/CD19 CAR T-cell therapy and autologous stem cell transplantation shows remarkable efficacy in treating Ph-negative B-ALL.

The FDA approves selumetinib for adults with neurofibromatosis type 1, offering new hope for treating inoperable plexiform neurofibromas.

Groundbreaking studies reveal the potential of cell therapies to achieve long-term remission in HPV-associated cancers, transforming treatment options for patients.

Giredestrant shows promise as a groundbreaking treatment for early-stage breast cancer, significantly improving disease-free survival rates.

During a live event, Moshe C. Ornstein, MD, MA, considered the trial design and outcomes of 2 trials of combination regimens for non–clear cell renal cell carcinoma.

Bispecific and trispecific antibodies show efficacy in multiple myeloma, moving into earlier lines of therapy.

OBI-902 receives FDA orphan drug designation for cholangiocarcinoma, promising new hope in treating this rare and aggressive cancer.

Small cell lung cancer treatment evolves with groundbreaking therapies, improving survival rates and offering new hope for patients in 2024 and beyond.

The FDA approves epcoritamab with rituximab and lenalidomide for relapsed follicular lymphoma, offering a new second-line treatment option.

DPTX3186 gains FDA fast track status, promising a novel treatment for gastric cancer with potential for significant patient impact.

A phase 1b/2 trial shows triplet therapy for advanced renal cell carcinoma is feasible but lacks significant response improvement over standard treatment.

The FDA grants fast track designation to a new noninvasive diagnostic agent for clear cell renal cell carcinoma, promising improved patient outcomes.

In an interview with Targeted Oncology, David J. Benjamin, MD, discussed findings on the global oncology workforce and their implications of insufficient access to cancer care.

Zanidatamab plus chemotherapy shows significant survival benefits for HER2-positive gastroesophageal adenocarcinoma, potentially transforming first-line treatment options.

Research highlights promising advancements in renal cell carcinoma treatments, focusing on HIF-2α inhibitors and combination therapies for improved patient outcomes.

At the 43rd Annual CFS meeting, John Allan, MD, highlighted ongoing efforts to advance the treatment paradigm for chronic lymphocytic leukemia.

Biomarker testing in non–small cell lung cancer evolves with new protein-based markers and AI, enhancing personalized treatment strategies for patients.

Avelumab shows modest, durable responses in advanced penile cancer, highlighting the need for innovative treatments in this challenging patient population.

Discover the latest advancements in oncology, including FDA approvals, groundbreaking trial results, and expert insights shaping cancer treatment today.

A phase 2 trial reveals single-dose carboplatin plus radiotherapy offers exceptional long-term survival and minimal toxicity for stage IIa/b seminoma patients.

The FDA clears the EXENT System, enhancing multiple myeloma diagnosis with automated workflows and improved sensitivity for clinical laboratories.

The FDA accepts 177Lu-edotreotide for GEP-NETs, showcasing significant survival benefits over everolimus in recent trials.

New research reveals that radiotherapy benefits prostate cancer patients with fewer metastases, refining treatment strategies for advanced cases.

A groundbreaking study reveals that less frequent dosing of pasritamig enhances immune response in advanced prostate cancer, challenging traditional treatment assumptions.

The FDA grants fast track designation to 4A10, a promising monoclonal antibody for treating relapsed acute lymphoblastic leukemia in children.

FOG-001 receives FDA fast track designation, promising new hope for desmoid tumor patients with its innovative approach to treatment.